Have an account? Log in.
I don't have an account.
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and maintains $48 price target.
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $50 to $45.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.